{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T02:45:16Z","timestamp":1777085116778,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K10606"],"award-info":[{"award-number":["24K10606"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11916-026-01482-8","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T02:16:04Z","timestamp":1777083364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of CGRP Monoclonal Antibodies in Japan, South Korea, and Taiwan: A Narrative Review"],"prefix":"10.1007","volume":"30","author":[{"given":"Keiko","family":"Ihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Hsiang","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Kano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2605-7200","authenticated-orcid":false,"given":"Tsubasa","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo-Seok","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mieko","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi Ji","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung-Kun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Chun","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3492-9902","authenticated-orcid":false,"given":"Shih-Pin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuu-Jiun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6221-1346","authenticated-orcid":false,"given":"Min Kyung","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"issue":"4","key":"1482_CR1","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A, American Headache Society. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024;64(4):333\u201341. https:\/\/doi.org\/10.1111\/head.14692.","journal-title":"Headache"},{"issue":"1","key":"1482_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention \u2013 2022 update. J Headache Pain. 2022;23(1):67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x.","journal-title":"J Headache Pain"},{"issue":"6","key":"1482_CR3","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1046\/j.1468-2982.2000.00085.x","volume":"20","author":"SJ Wang","year":"2000","unstructured":"Wang SJ, Fuh JL, Young YH, Lu SR, Shia BC. Prevalence of migraine in Taipei, Taiwan: a population-based survey. Cephalalgia. 2000;20(6):566\u201372. https:\/\/doi.org\/10.1046\/j.1468-2982.2000.00085.x.","journal-title":"Cephalalgia"},{"issue":"16","key":"1482_CR4","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1177\/0333102412461401","volume":"32","author":"YF Wang","year":"2012","unstructured":"Wang YF, Fuh JL, Chen SP, Wu JC, Wang SJ. Clinical correlates and diagnostic utility of osmophobia in migraine. Cephalalgia. 2012;32(16):1180\u20138. https:\/\/doi.org\/10.1177\/0333102412461401.","journal-title":"Cephalalgia"},{"issue":"3","key":"1482_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14030734","volume":"14","author":"MK Kang","year":"2025","unstructured":"Kang MK, Sohn JH, Cha MJ, Kim YH, Hong Y, Im HJ, et al. One-year compliance after calcitonin gene-related peptide monoclonal antibody therapy for migraine patients in a real-world setting: a multicenter cross-sectional study. J Clin Med. 2025;14(3):734. https:\/\/doi.org\/10.3390\/jcm14030734.","journal-title":"J Clin Med"},{"issue":"1","key":"1482_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01737-y","volume":"25","author":"T Takizawa","year":"2024","unstructured":"Takizawa T, Ihara K, Watanabe N, Takemura R, Takahashi N, Miyazaki N, et al. CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache society. J Headache Pain. 2024;25(1):39. https:\/\/doi.org\/10.1186\/s10194-024-01737-y.","journal-title":"J Headache Pain"},{"issue":"8","key":"1482_CR7","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442\u201354. https:\/\/doi.org\/10.1177\/0333102418779543.","journal-title":"Cephalalgia"},{"issue":"24","key":"1482_CR8","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211-21. https:\/\/doi.org\/10.1212\/WNL.0000000000006640.","journal-title":"Neurology"},{"issue":"9","key":"1482_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16372","volume":"31","author":"YF Wang","year":"2024","unstructured":"Wang YF, Yang FC, Chen LA, Chang TY, Su HC, Yang CP, et al. Comparative effectiveness and tolerability of calcitonin gene-related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: a multicenter, real\u2010world study in Taiwan. Eur J Neurol. 2024;31(9):e16372. https:\/\/doi.org\/10.1111\/ene.16372.","journal-title":"Eur J Neurol"},{"issue":"10","key":"1482_CR10","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1111\/head.13652","volume":"59","author":"F Sakai","year":"2019","unstructured":"Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Lenz R, Wang Y, et al. A randomized phase 2 study of erenumab for the prevention of episodic migraine in Japanese adults. Headache. 2019;59(10):1731\u201342. https:\/\/doi.org\/10.1111\/head.13652.","journal-title":"Headache"},{"issue":"7","key":"1482_CR11","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/head.14178","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Kim BK, Tatsuoka Y, Imai N, Ning X, et al. Efficacy and safety of fremanezumab for episodic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache. 2021;61(7):1102\u201311. https:\/\/doi.org\/10.1111\/head.14178.","journal-title":"Headache"},{"issue":"4","key":"1482_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/head.14096","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Cheng S, Numachi Y, et al. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine. Headache. 2021;61(4):653\u201361. https:\/\/doi.org\/10.1111\/head.14096.","journal-title":"Headache"},{"issue":"5","key":"1482_CR13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3988\/jcn.2022.0180","volume":"19","author":"BK Kim","year":"2023","unstructured":"Kim BK, Cho SJ, Han JH, Dell\u2019Agnello G, Panni T, Kim M, et al. Efficacy and safety of galcanezumab as a preventive treatment for episodic migraine in South Korean patients: a post-hoc analysis of a phase 3 clinical trial. J Clin Neurol. 2023;19(5):483\u201394. https:\/\/doi.org\/10.3988\/jcn.2022.0180.","journal-title":"J Clin Neurol"},{"issue":"7","key":"1482_CR14","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/head.14169","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Kim BK, Igarashi H, Hirata K, Takeshima T, et al. Efficacy and safety of fremanezumab for chronic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache. 2021;61(7):1092\u2013101. https:\/\/doi.org\/10.1111\/head.14169.","journal-title":"Headache"},{"issue":"1","key":"1482_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01514-9","volume":"23","author":"S Yu","year":"2022","unstructured":"Yu S, Kim BK, Wang H, Zhou J, Wan Q, Yu T, et al. A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study. J Headache Pain. 2022;23(1):146. https:\/\/doi.org\/10.1186\/s10194-022-01514-9.","journal-title":"J Headache Pain"},{"issue":"10","key":"1482_CR16","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1080\/03007995.2020.1815181","volume":"36","author":"CP Yang","year":"2020","unstructured":"Yang CP, Lee CF, Dell\u2019Agnello G, Hundemer HP, Lipsius S, Wang SJ. Safety and efficacy of galcanezumab in Taiwanese patients: a post-hoc analysis of phase 3 studies in episodic and chronic migraine. Curr Med Res Opin. 2020;36(10):1653\u201366. https:\/\/doi.org\/10.1080\/03007995.2020.1815181.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"1482_CR17","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40264-021-01119-2","volume":"44","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Ning X, Ishida M, Usuki C, Iba K, et al. Long-term safety and tolerability of fremanezumab for migraine preventive treatment in Japanese outpatients: a multicenter, randomized, open-label study. Drug Saf. 2021;44(12):1355\u201364. https:\/\/doi.org\/10.1007\/s40264-021-01119-2.","journal-title":"Drug Saf"},{"issue":"6","key":"1482_CR18","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/14740338.2021.1866536","volume":"20","author":"K Hirata","year":"2021","unstructured":"Hirata K, Takeshima T, Sakai F, Tatsuoka Y, Suzuki N, Igarashi H, et al. A long-term open-label safety study of galcanezumab in Japanese patients with migraine. Expert Opin Drug Saf. 2021;20(6):721\u201333. https:\/\/doi.org\/10.1080\/14740338.2021.1866536.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"1482_CR19","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/head.14138","volume":"61","author":"T Takeshima","year":"2021","unstructured":"Takeshima T, Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R, et al. Erenumab treatment for migraine prevention in Japanese patients: efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study. Headache. 2021;61(6):927\u201335. https:\/\/doi.org\/10.1111\/head.14138.","journal-title":"Headache"},{"issue":"8","key":"1482_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-068616","volume":"13","author":"K Hirata","year":"2023","unstructured":"Hirata K, Takeshima T, Sakai F, Numachi Y, Yoshida R, Koukakis R, et al. Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial. BMJ Open. 2023;13(8):e068616. https:\/\/doi.org\/10.1136\/bmjopen-2022-068616.","journal-title":"BMJ Open"},{"issue":"3","key":"1482_CR21","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40120-024-00602-z","volume":"13","author":"T Takeshima","year":"2024","unstructured":"Takeshima T, Doi H, Ooba S, Tanji Y, Ozeki A, Komori M. Clinical evaluation after discontinuation of galcanezumab in Japanese patients with episodic and chronic migraine: analysis of a randomized, placebo-controlled trial and open-label extension study. Neurol Ther. 2024;13(3):697\u2013714. https:\/\/doi.org\/10.1007\/s40120-024-00602-z.","journal-title":"Neurol Ther"},{"issue":"1","key":"1482_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01753-y","volume":"25","author":"R Oliveira","year":"2024","unstructured":"Oliveira R, Gil-Gouveia R, Puledda F. CGRP-targeted medication in chronic migraine \u2013 systematic review. J Headache Pain. 2024;25(1):51. https:\/\/doi.org\/10.1186\/s10194-024-01753-y.","journal-title":"J Headache Pain"},{"issue":"10","key":"1482_CR23","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s11916-022-01077-z","volume":"26","author":"AM Murray","year":"2022","unstructured":"Murray AM, Stern JI, Robertson CE, Chiang CC. Real-world patient experience of CGRP-targeting therapy for migraine: a narrative review. Curr Pain Headache Rep. 2022;26(10):783\u201394. https:\/\/doi.org\/10.1007\/s11916-022-01077-z.","journal-title":"Curr Pain Headache Rep"},{"issue":"6","key":"1482_CR24","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2169\/internalmedicine.4037-24","volume":"64","author":"K Ihara","year":"2025","unstructured":"Ihara K, Takahashi N, Ohtani S, Watanabe N, Ishizuchi K, Takemura R, et al. Real-world efficacy of erenumab on migraine-associated symptoms and patient-reported satisfaction levels: a retrospective study in Japan. Intern Med. 2025;64(6):825\u201331. https:\/\/doi.org\/10.2169\/internalmedicine.4037-24.","journal-title":"Intern Med"},{"issue":"1","key":"1482_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03449-3","volume":"23","author":"S Ohtani","year":"2023","unstructured":"Ohtani S, Watanabe N, Ihara K, Takahashi N, Miyazaki N, Ishizuchi K, et al. Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study. BMC Neurol. 2023;23(1):404. https:\/\/doi.org\/10.1186\/s12883-023-03449-3.","journal-title":"BMC Neurol"},{"issue":"9","key":"1482_CR26","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1007\/s00415-023-11788-x","volume":"270","author":"K Suzuki","year":"2023","unstructured":"Suzuki K, Suzuki S, Shiina T, Haruyama Y, Fujita H, Funakoshi K, et al. Could efficacy at 1 week after galcanezumab administration for patients with migraine predict responders at 3 months? A real world study. J Neurol. 2023;270(9):4377\u201384. https:\/\/doi.org\/10.1007\/s00415-023-11788-x.","journal-title":"J Neurol"},{"issue":"5","key":"1482_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231177649","volume":"43","author":"K Suzuki","year":"2023","unstructured":"Suzuki K, Suzuki S, Shiina T, Tatsumoto M, Fujita H, Haruyama Y, et al. Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: a 12-month, single-center, observational real-world study in Japan. Cephalalgia. 2023;43(5):3331024231177649. https:\/\/doi.org\/10.1177\/03331024231177649.","journal-title":"Cephalalgia"},{"issue":"1","key":"1482_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-022-03041-1","volume":"22","author":"T Takizawa","year":"2022","unstructured":"Takizawa T, Ohtani S, Watanabe N, Miyazaki N, Ishizuchi K, Sekiguchi K, et al. Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis. BMC Neurol. 2022;22(1):512. https:\/\/doi.org\/10.1186\/s12883-022-03041-1.","journal-title":"BMC Neurol"},{"issue":"1","key":"1482_CR29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12883-023-03521-y","volume":"24","author":"M Shibata","year":"2024","unstructured":"Shibata M, Fujita K, Hoshino E, Minami K, Koizumi K, Okada S, et al. Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers. BMC Neurol. 2024;24(1):32. https:\/\/doi.org\/10.1186\/s12883-023-03521-y.","journal-title":"BMC Neurol"},{"issue":"1","key":"1482_CR30","doi-asserted-by":"publisher","DOI":"10.4212\/cjhp.3382","volume":"77","author":"A Zovi","year":"2024","unstructured":"Zovi A, Langella R, Aloisi AC, De Giorgio C, Del Vecchio M, Dondi C, et al. Real-world effectiveness of calcitonin gene-related peptide-binding monoclonal antibodies for migraine prevention: a systematic review. Can J Hosp Pharm. 2024;77(1):e3382. https:\/\/doi.org\/10.4212\/cjhp.3382.","journal-title":"Can J Hosp Pharm"},{"issue":"8","key":"1482_CR31","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1177\/03331024221076481","volume":"42","author":"S Kwon","year":"2022","unstructured":"Kwon S, Gil YE, Lee MJ. Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients. Cephalalgia. 2022;42(8):705\u201314. https:\/\/doi.org\/10.1177\/03331024221076481.","journal-title":"Cephalalgia"},{"issue":"1","key":"1482_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01556-7","volume":"24","author":"K Ihara","year":"2023","unstructured":"Ihara K, Ohtani S, Watanabe N, Takahashi N, Miyazaki N, Ishizuchi K, et al. Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study. J Headache Pain. 2023;24(1):23. https:\/\/doi.org\/10.1186\/s10194-023-01556-7.","journal-title":"J Headache Pain"},{"issue":"7","key":"1482_CR33","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1007\/s10072-023-06683-2","volume":"44","author":"HC Lee","year":"2023","unstructured":"Lee HC, Cho S, Kim BK. Predictors of response to galcanezumab in patients with chronic migraine: a real-world prospective observational study. Neurol Sci. 2023;44(7):2455\u201363. https:\/\/doi.org\/10.1007\/s10072-023-06683-2.","journal-title":"Neurol Sci"},{"issue":"1","key":"1482_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-42110-4","volume":"13","author":"SA Kim","year":"2023","unstructured":"Kim SA, Jang H, Lee MJ. Predictors of galcanezumab response in a real-world study of Korean patients with migraine. Sci Rep. 2023;13(1):14825. https:\/\/doi.org\/10.1038\/s41598-023-42110-4.","journal-title":"Sci Rep"},{"issue":"1","key":"1482_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-72282-6","volume":"14","author":"D Danno","year":"2024","unstructured":"Danno D, Imai N, Kitamura S, Ishizaki K, Kikui S, Takeshima T. Efficacy of galcanezumab in migraine central sensitization. Sci Rep. 2024;14(1):21824. https:\/\/doi.org\/10.1038\/s41598-024-72282-6.","journal-title":"Sci Rep"},{"issue":"4","key":"1482_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e26568","volume":"10","author":"K Suzuki","year":"2024","unstructured":"Suzuki K, Suzuki S, Shiina T, Haruyama Y, Kobayashi S, Shioda M, et al. Real-world effectiveness of erenumab in Japanese patients with migraine. Heliyon. 2024;10(4):e26568. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e26568.","journal-title":"Heliyon"},{"key":"1482_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2023.120811","volume":"453","author":"K Ihara","year":"2023","unstructured":"Ihara K, Ohtani S, Watanabe N, Takahashi N, Miyazaki N, Takemura R, et al. Switching between anti-calcitonin gene-related peptide monoclonal antibodies: a comparison of monthly and quarterly dosing. J Neurol Sci. 2023;453:120811. https:\/\/doi.org\/10.1016\/j.jns.2023.120811.","journal-title":"J Neurol Sci"},{"key":"1482_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1220285","volume":"14","author":"S Suzuki","year":"2023","unstructured":"Suzuki S, Suzuki K, Shiina T, Haruyama Y, Hirata K. Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan. Front Neurol. 2023;14:1220285. https:\/\/doi.org\/10.3389\/fneur.2023.1220285.","journal-title":"Front Neurol"},{"issue":"11","key":"1482_CR39","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/pm\/pnae050","volume":"25","author":"S Kikui","year":"2024","unstructured":"Kikui S, Daisuke D, Miyahara J, Sugiyama H, Ota K, Murakata K, et al. Effectiveness of fremanezumab treatment in patients with migraine headache. Pain Med. 2024;25(11):664\u201370. https:\/\/doi.org\/10.1093\/pm\/pnae050.","journal-title":"Pain Med"},{"issue":"14","key":"1482_CR40","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.2169\/internalmedicine.4360-24","volume":"64","author":"K Oshima","year":"2025","unstructured":"Oshima K, Ihara K, Watanabe N, Takemura R, Ishizuchi K, Takahashi N, et al. Efficacy and safety of switching between anti-CGRP monoclonal antibodies: a detailed monthly and long-term follow-up study and literature review. Intern Med. 2025;64(14):2114\u201323. https:\/\/doi.org\/10.2169\/internalmedicine.4360-24.","journal-title":"Intern Med"},{"issue":"1","key":"1482_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01850-y","volume":"25","author":"YC An","year":"2024","unstructured":"An YC, Hung KS, Liang CS, Tsai CK, Tsai CL, Chen SJ, et al. Genetic variants associated with response to anti-CGRP monoclonal antibody therapy in a chronic migraine Han Chinese population. J Headache Pain. 2024;25(1):149. https:\/\/doi.org\/10.1186\/s10194-024-01850-y.","journal-title":"J Headache Pain"},{"key":"1482_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2023.122785","volume":"455","author":"K Ihara","year":"2023","unstructured":"Ihara K, Ohtani S, Watanabe N, Takahashi N, Hori S, Nakahara J, et al. Response to letter: \u201cSwitching from calcitonin gene-related peptide monoclonal antibody monthly to fremanezumab quarterly based on the patient\u2019s preferred dosing schedule\u201d by Suzuki et al. J Neurol Sci. 2023;455:122785. https:\/\/doi.org\/10.1016\/j.jns.2023.122785.","journal-title":"J Neurol Sci"},{"issue":"23","key":"1482_CR43","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.2169\/internalmedicine.1471-22","volume":"62","author":"Y Ito","year":"2023","unstructured":"Ito Y, Mitsufuji T, Okada M, Fujita S, Yokoyama R, Kawasaki H, et al. Early effect of calcitonin gene-related peptide monoclonal antibodies in migraine with medication overuse: a single-center retrospective study. Intern Med. 2023;62(23):3455\u201360. https:\/\/doi.org\/10.2169\/internalmedicine.1471-22.","journal-title":"Intern Med"},{"key":"1482_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2023.122786","volume":"455","author":"S Suzuki","year":"2023","unstructured":"Suzuki S, Suzuki K, Shiina T, Kobayashi S, Shioda M, Hirata K. Switching from calcitonin gene-related peptide monoclonal antibody monthly to fremanezumab quarterly based on the patient\u2019s preferred dosing schedule. J Neurol Sci. 2023;455:122786. https:\/\/doi.org\/10.1016\/j.jns.2023.122786.","journal-title":"J Neurol Sci"},{"issue":"3","key":"1482_CR45","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3988\/jcn.2023.0311","volume":"20","author":"MS Youn","year":"2024","unstructured":"Youn MS, Kim N, Lee MJ, Kim M. Treatment outcome after switching from galcanezumab to fremanezumab in patients with migraine. J Clin Neurol. 2024;20(3):300\u20135. https:\/\/doi.org\/10.3988\/jcn.2023.0311.","journal-title":"J Clin Neurol"},{"issue":"2","key":"1482_CR46","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/head.14903","volume":"65","author":"M Romozzi","year":"2025","unstructured":"Romozzi M, Munaf\u00f2 A, Burgalassi A, De Cesaris F, Vigani G, Altamura C, et al. Pharmacological differences and switching among anti-CGRP monoclonal antibodies: a narrative review. Headache. 2025;65(2):342\u201352. https:\/\/doi.org\/10.1111\/head.14903.","journal-title":"Headache"},{"issue":"11","key":"1482_CR47","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1212\/WNL.0000000000207292","volume":"101","author":"P Barbanti","year":"2023","unstructured":"Barbanti P, Aurilia C, Egeo G, Torelli P, Proietti S, Cevoli S, et al. Late response to anti-CGRP monoclonal antibodies in migraine: a multicenter prospective observational study. Neurology. 2023;101(11):482\u20138. https:\/\/doi.org\/10.1212\/WNL.0000000000207292.","journal-title":"Neurology"},{"issue":"5","key":"1482_CR48","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s00415-023-12103-4","volume":"271","author":"P Barbanti","year":"2024","unstructured":"Barbanti P, Aurilia C, Egeo G, Proietti S, D\u2019Onofrio F, Torelli P, et al. Ultra-late response (>\u200924 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study. J Neurol. 2024;271(5):2434\u201343. https:\/\/doi.org\/10.1007\/s00415-023-12103-4.","journal-title":"J Neurol"},{"issue":"7","key":"1482_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/ph16070934","volume":"16","author":"JB Hong","year":"2023","unstructured":"Hong JB, Lange KS, Overeem LH, Triller P, Raffaelli B, Reuter U. A scoping review and meta-analysis of anti-CGRP monoclonal antibodies: predicting response. Pharmaceuticals (Basel). 2023;16(7):934. https:\/\/doi.org\/10.3390\/ph16070934.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"12","key":"1482_CR50","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s11916-023-01183-6","volume":"28","author":"C S\u00e1nchez-Rodr\u00edguez","year":"2024","unstructured":"S\u00e1nchez-Rodr\u00edguez C, Gago-Veiga AB, Garc\u00eda-Azor\u00edn D, Guerrero-Peral \u00c1L, Gonzalez-Martinez A. Potential predictors of response to CGRP monoclonal antibodies in chronic migraine: real-world data. Curr Pain Headache Rep. 2024;28(12):1265\u201372. https:\/\/doi.org\/10.1007\/s11916-023-01183-6.","journal-title":"Curr Pain Headache Rep"},{"issue":"1","key":"1482_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01498-6","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Egeo G, Aurilia C, Altamura C, D\u2019Onofrio F, Finocchi C, et al. Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain. 2022;23(1):138. https:\/\/doi.org\/10.1186\/s10194-022-01498-6.","journal-title":"J Headache Pain"},{"issue":"9","key":"1482_CR52","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/head.14806","volume":"64","author":"CC Chiang","year":"2024","unstructured":"Chiang CC, Schwedt TJ, Dumkrieger G, Wang L, Chao CJ, Ouellette HA, et al. Advancing toward precision migraine treatment: predicting responses to preventive medications with machine learning models based on patient and migraine features. Headache. 2024;64(9):1094\u2013108. https:\/\/doi.org\/10.1111\/head.14806.","journal-title":"Headache"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-026-01482-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-026-01482-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-026-01482-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T02:16:05Z","timestamp":1777083365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-026-01482-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1482"],"URL":"https:\/\/doi.org\/10.1007\/s11916-026-01482-8","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"KI received a Postdoctoral Fellowship Grant from the American Heart Association, with funds paid to her institution. TsT is a consultant\/advisor and\/or serves on advisory boards for Eli Lilly, Otsuka, Amgen, Daiichi Sankyo, Pfizer, Teijin, and AbbVie, and has received speaker honoraria from Daiichi Sankyo, Eli Lilly, Otsuka, Amgen, Pfizer, Sawai, Kyowa Kirin, Eisai, and Takeda, as well as grant\/funding from Eli Lilly, Pfizer, and Tsumura, outside the submitted work. MJL has received honoraria as a consultant or speaker for Eli Lilly, Teva, AbbVie, Sanofi-Aventis, SK Pharm, and YuYu Pharma; has been the principal investigator or co-investigator in trials sponsored by Eli Lilly, Novartis, Teva (Otsuka), Allergan, Lundbeck, Biohaven, Yuhan Company, Ildong Pharm, Samjin Pharm, and Dong-A ST; and has received research support from the National Research Foundation of Korea. BK is a member of the Editorial Board of the Journal of Clinical Neurology and has received honoraria as a moderator, speaker, or advisor from AbbVie Korea, Teva-Handok, Lundbeck Korea, Pfizer Korea, Organon Korea, Dong-A Pharm, YuYu Pharm, SK Pharm, and Ildong Pharm. CC has served as a consultant for Pfizer, AbbVie, Amneal, Satsuma, and eNeura, and has received research support from the American Heart Association, Lundbeck, and Pfizer, with funds paid to her institution. SPC has served as an Associate Editor of the Journal of Headache and Pain and received speaker honoraria from AbbVie. SJW has received honoraria as a moderator from AbbVie, Biogen, Eli Lilly, Hava Biopharma, and Pfizer; consulting fees from AbbVie, Eli Lilly Taiwan, Percept Co., and Pfizer Taiwan; and has been the PI in trials sponsored by Eli Lilly, Lundbeck, and Novartis. He has received research grants from the Taiwan branches of Eli Lilly, Novartis, and Orient Europharma. MKC received lecture honoraria from Handok-Teva, AbbVie, Organon Korea, and Ildong Pharmaceutical Company. He was a site investigator for a multicentre trial sponsored by Pfizer, AbbVie, and Ildong Pharmaceutical Company. He has received lecture honoraria from Handok-Teva, AbbVie, Organon Korea, and Ildong Pharmaceutical Company over the past 24 months. He received grants from the Korea Health Industry Development Institute (HV22C0106), and a National Research Foundation of Korea grant from the Korean Government (MSIT; 2022R1A2C1091767). TaT is an advisor for Teijin and Hedgcock MedTech, receives honoraria from Otsuka, Amgen, Eli Lilly Japan, Sawai, and Daiichi-Sankyo, and grants for commissioned\/joint research from Pfizer, Lundbeck, Abbie, and Eli Lilly Japan. YFW has received personal fees as an advisor or a speaker from Allergan\/AbbVie, Boehringer Ingelheim, Chugai, Daiichi-Sankyo, Eli Lilly, Hava Bio-Pharma, Lundbeck, Novartis, Orient EuroPharma, Pfizer, Sanofi, Teva, UCB, and Viatris. He has received research grants from the Taiwan National Science and Technology Council and Taipei Veterans General Hospital.YHL has received speaker honoraria from Orient EuroPharma, HAVA Bio-Pharma, and Pfizer Taiwan, as well as travel funding from Pfizer. He has also received research grants from Taipei Veterans General Hospital and the Vivian W. Yen Neurological Foundation. SPC and SJW are the editors of Topical Collection on Chronic Daily Headache of Current Pain and Headache Reports, but they are not involved in the journal\u2019s peer review process or decisions related to this manuscript. YK, WSH, and MI declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"54"}}